Skip to main content
. 2020 Oct 30;106(2):e520–e533. doi: 10.1210/clinem/dgaa792

Table 3.

Changes in Circulating IGFBP With Tesamorelin Treatment

Protein Effect size (log2 fold change) 95% CI of effect size P value
IGFBP-1 0.64 (0.18, 1.11) 0.01
IGFBP-2 −0.46 (−0.71, −0.21) 0.0007
IGFBP-3 0.24 (0.01, 0.47) 0.05
IGFBP-6 −0.23 (−0.44, −0.02) 0.04
IGFBP-7 0.00 (−0.23, 0.24) 0.98

Effect size and P value for the time × randomization interaction in mixed effects modeling for continuous repeated measures in the entire study cohort (N = 61).